BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23955071)

  • 1. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.
    Berger A; Quast SA; Plötz M; Kuhn NF; Trefzer U; Eberle J
    J Invest Dermatol; 2014 Feb; 134(2):430-440. PubMed ID: 23955071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
    Gillespie S; Borrow J; Zhang XD; Hersey P
    Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax.
    Berger A; Quast SA; Plötz M; Kammermeier A; Eberle J
    Cell Death Dis; 2013 Jan; 4(1):e477. PubMed ID: 23348591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
    Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
    Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC.
    Quast SA; Berger A; Buttstädt N; Friebel K; Schönherr R; Eberle J
    PLoS One; 2012; 7(6):e39290. PubMed ID: 22723988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis.
    Han J; Goldstein LA; Gastman BR; Rabinowich H
    J Biol Chem; 2006 Apr; 281(15):10153-63. PubMed ID: 16478725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
    Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
    Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins.
    Werneburg NW; Guicciardi ME; Bronk SF; Kaufmann SH; Gores GJ
    J Biol Chem; 2007 Sep; 282(39):28960-28970. PubMed ID: 17686764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
    Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
    J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the TRAIL to overcome BRAF-inhibitor resistance.
    Geserick P; Herlyn M; Leverkus M
    J Invest Dermatol; 2014 Feb; 134(2):315-318. PubMed ID: 24424456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
    Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BH3-only protein Bim(L) overrides Bcl-2-mediated apoptosis resistance in melanoma cells.
    Plötz M; Gillissen B; Quast SA; Berger A; Daniel PT; Eberle J
    Cancer Lett; 2013 Jul; 335(1):100-8. PubMed ID: 23402819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
    Zhu H; Guo W; Zhang L; Wu S; Teraishi F; Davis JJ; Dong F; Fang B
    Cancer Biol Ther; 2005 Jul; 4(7):781-6. PubMed ID: 16082182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1.
    Gao Z; Shang Q; Liu Z; Deng C; Guo C
    Oncotarget; 2015 Nov; 6(34):36338-53. PubMed ID: 26462148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
    Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
    Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
    Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
    Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.